MedTrace Logo

A Retrospective Evaluation of Superficial Radiation Therapy (SRT) and Keloid Scars.

NCT03693924 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2018-10-03

No results posted yet for this study

Summary

Keloid formation in response to skin trauma inflicts about 18 million individuals. A key impediment in successful treatment of keloids is that the predominant treatments, particularly surgical excision and shaving, tend to initiate the regrowth of the keloid at the excision site, and therefore, recurrence rates are high. There is much evidence to demonstrate that following surgical excision procedures with a course of radiation therapy can significantly reduce recurrence rates to as little as 10% or below. This retrospective study is to evaluate this claim.

Conditions

  • Keloid Scar

Interventions

RADIATION

SRT-100

The SRT-100™ is a simple painless non-invasive in-office procedure that is approved by the U.S. Food and Drug Administration (U.S. FDA) to treat keloids caused by surgery or injury by delivering a precise, calibrated dose of Superficial Radiation Therapy (SRT) that only goes skin deep.

Sponsors & Collaborators

  • Sensus Healthcare

    lead INDUSTRY

Principal Investigators

  • Brian Berman, M.D.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-15
Primary Completion
2019-02-16
Completion
2019-02-16
FDA Device
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03693924 on ClinicalTrials.gov